Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nimbus Therapeutics

www.nimbustx.com

Latest From Nimbus Therapeutics

Deal Watch: Altimmune Moves Into NASH With Purchase Of Spitfire

Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.

Deals Business Strategies

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine

Bristol Engineers An Oral TYK2 Inhibitor With Biologic-Like Efficacy That Rivals JAK Safety

The company's first set of Phase II data for its oral, selective TYK2 inhibitor in psoriasis showed a consistent dose response as well as safety that could rival the related JAK inhibitor class. BMS-986165 already is in Phase III for psoriasis; it's in Phase II for lupus and Crohn's disease.

Clinical Trials Drug Safety

Venture Funding Deals: Alector, Ascentage, Gossamer And Compass Lead Summer Rounds

Compass raises $132m in Series A as it moves from screening to the clinic, and start-up HotSpot Therapeutics comes out of stealth mode with a $45m Series A financing co-led by Atlas Venture and Sofinnova Partners.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
      • Bioinformatics
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Alias(es)
  • Nimbus Discovery LLC
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Nimbus Therapeutics
  • Senior Management
  • Donald W Nicholson, PhD, CEO
    Jeb Keiper, CFO & CBO
    Annie C Chen, MD, CMO
    Adrian Ray, PhD, SVP, Discovery Biology
    Peter Tummino, PhD, CSO
  • Contact Info
  • Nimbus Therapeutics
    Phone: (857) 999-2009
    130 Prospect St.
    Ste. 301
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register